TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07695701: An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Sponsor: Eidos Therapeutics, a BridgeBio company · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT07695701 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07695701 Rescue Dossier →